scholarly journals Prognostic evaluation in head and neck cancer patients: a clinicoimaging tertiary care center study

2021 ◽  
Vol 8 (10) ◽  
pp. 4831
Author(s):  
N. Kavya Keerthika ◽  
D. Sri Veda ◽  
M. P. V. Prabhat ◽  
G. Sarat ◽  
Gunmeet Maini
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
World Health ◽  
Treatment Modalities ◽  
Prognostic Evaluation ◽  
Etiological Factors

Background: The occurrence of the head and neck cancers (HNC) is increasing day by day. These have been associated with multiple etiological factors, and early diagnosis has a prime role in the patient's prognosis and overall survival. Prognostic evaluation in head and neck cancer patients utilizing clinical incidence and imaging outcomes.Methods: The study sample included 217 confirmed HNC patients’ data obtained from the tertiary cancer care centre were analysed to assess the prognosis and be subjected to statistical analysis.Results: Out of all HNC, cancer pertaining to the lip and oral cavity was the most common variety with 65.89% and most of the HNC occurred in men of about 97%, suggesting a strong association with adverse oral habits.Conclusions: We conclude that the current scenario of HNC’s progression and treatment modalities in Andhra Pradesh were in comparison to the World Health Organization (WHO) data suggests an increase in the awareness of the etiological factors and the disease progression. Though various advanced imaging and treatment modalities are available, the patients' prognosis is untethered due to low socio-economic status in this region.

scholarly journals OPERATING ON HEAD AND NECK CANCERS DURING COVID-19 PANDEMIC: OUR EXPERIENCE IN A TERTIARY CARE SURGICAL ONCOLOGY CENTER IN CENTRAL INDIA

2020 ◽  
pp. 72-73
Author(s):  
Sandeep Ghosh ◽  
Bonny Joseph ◽  
Vinod Dhakad ◽  
Sanjay Desai
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
Central India ◽  
Surgical Oncology ◽  
Cancer Management ◽  
Global Pandemic

WHO declared the COVID-19 outbreak to be a global pandemic on March 11, 2020. We hereby present the ongoing challenges, and the protocol and algorithms followed by us right from diagnosis, surgery and follow up of 50 head and neck cancer patients during the time of covid-19 pandemic at a tertiary care center in central India. Of the 50 head and neck cancer patients operated we had 16(32%) Ca buccal mucosa cases, 13(26%) cases of ca lower alveolus, 9 (18%) ca tongue cases, 5 (10%) ca maxilla, 3 (6%) ca larynx, 2 (4%) ca lip and 2 (4%) ca thyroid cases. It is prudent to consider every patient as covid carrier as community spread has already occurred in our country and take necessary precautions while examining all patients. Cancer Management is semi-emergency. The precautions taken by us are considered to be standard and have allowed us to perform head and neck cancer surgeries safely in this Covid-19 pandemic.

scholarly journals Quantitative Assessment of Serum Magnesium Levels in Head and Neck Cancer: A Tertiary Hospital Based Case Control Study

2021 ◽  
pp. 249-257
Author(s):  
Surender Kumar ◽  
Neha Salaria ◽  
Deepak Verma ◽  
Uma Garg ◽  
Monika Verma
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Case Control Study ◽  
Serum Magnesium ◽  
Tertiary Care ◽  
Case Control ◽  
Control Group ◽  
Control Study

Background- Head and neck squamous cell carcinomas(HNSCC) are one of the most widespread malignancies worldwide. Trace elements such as magnesium are essential at cellular level, and it has been suggested that magnesium plays a role in carcinogenesis. Methods- A hospital based case control study was conducted in a tertiary care medical college with an aim to determine the levels of serum magnesium in patients with head and neck cancer and to  compare  the  levels  of  serum  magnesium  of head and neck cancer patients   with healthy matched control  group  and  derive significance if any. Results- HNSCC was mainly found in males of age group 46 to 55 years. The mean serum Mg value of head and neck cancer patients was 0.71± 0.18 mmol/l while that seen in controls was 0.85± 0.09 mmol/l which was significantly lower(p<0.001). Average serum magnesium levels in stages I, II, III and IV were 0.85, 0.849, 0.682 and 0.554 mmol/l respectively, and a statistically significant association was determined between the two. Conclusion- As the stage of cancer progressed, average magnesium levels decreased congruently, hence establishing that magnesium levels were undeniably correlated to onset as well as progression of HNC. These evidences could be utilized to identify role of magnesium asa potential prognostic biomarker to assess progression of disease or clinical response to various modes of therapy in head and neck cancer patients.

Head and Neck Cancer—A Clinicopathological Study in a Tertiary Care Center

2008 ◽  
Vol 100 (6) ◽  
pp. 690-697 ◽  
Author(s):  
Bukola F Adeyemi ◽  
Lola V Adekunle ◽  
Bamidele M Kolude ◽  
Effiong E.U. Akang ◽  
Jonathan O. Lawoyin
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Clinicopathological Study

scholarly journals Less is Enough: Outcome of Bimodality Definitive Concurrent Chemoradiation does not Differ from that of Trimodality Upfront Neck Dissection Followed by Adjuvant Treatment for >6 cm Bulky Lymph Node (N3) Head and Neck Cancer

2019 ◽  
Author(s):  
Wan-Yu Chen ◽  
Tseng-Cheng Chen ◽  
Shih-Fan Lai ◽  
Tony Hsiang-Kuang Liang ◽  
Bing-Shen Huang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Dissection ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Primary Tumor ◽  
Treatment Modalities ◽  
Recurrence Free Survival ◽  
Tumor Treatment ◽  
Free Survival

Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.

scholarly journals Comparison of Open Gastrostomy and Percutaneous Endoscopic Gastrostomy in Head and Neck Cancer Patients, Tertiary Care Hospital Experience

2021 ◽  
Vol 5 (4) ◽  
pp. 166-170
Author(s):  
Talha Ahmed Qureshi ◽  
◽  
Shabir Akhtar ◽  
Sohail Awan ◽  
Amir Sharif ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Percutaneous Endoscopic Gastrostomy ◽  
Neck Cancer ◽  
Tertiary Care ◽  
Ethical Review ◽  
Care Hospital ◽  
Endoscopic Gastrostomy ◽  
Peristomal Infection

Abstract: Objective: The current study was conducted to review and compare PEG and Gastrostomy in terms of early complications in head and neck cancer patients. Materials and Methods: This was prospective comparative study recruited total 60 patients as per the inclusion criteria, 30 in each group. Patients were assigned to the groups based on the surgeon’s choice. Ethical clearance was taken from ethical review board. Informed consent was taken from patients before enrolling them into the study. Non-probability consecutive sampling technique was used to enroll study participants. Data was collected on pre-designed performa and analyzed using SPSS version 16. Setting: Section of Otolaryngology, Department of Surgery, Aga Khan University Hospital Karachi. Results: The two groups did not differ on basis of age, gender and tumor site. The outcomes variables including pain and bleeding from post-operative day1 to day 5 were significantly lower in patients who underwent PEG placement as compared to patients whom we performed OPEN gastrostomy. None the patient had peristomal infection in PEG group throughout the study. However, difference between the groups was statistically significant from post-operative day 3 to day 5. Conclusion: In our study, PEG was associated with lesser complications than open gastrostomy. Recently clinicians are using newer modalities like radiological and laparoscopic gastrostomy at various centres in Pakistan as the first option for placing feeding gastrostomy. Therefore, future studies are warranted to compare their efficacy and post-operative complications PEG. Keywords: Head and neck cancer, Open gastrostomy, Percutaneous endoscopic gastrostomy, Complications, Pain, Peristomal infection, Bleeding

P-40 Radiotherapy with curative intent in head and neck cancer – Experience from a tertiary care center

Oral Oncology ◽  
2021 ◽  
Vol 118 ◽  
pp. 2
Author(s):  
André Laranja ◽  
Diana Moreira ◽  
Isabel Reis ◽  
Isabel Rodrigues ◽  
Fausto Sousa ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Curative Intent ◽  
Cancer Experience

scholarly journals Clinical Factors Associated With Cost in Head and Neck Cancer: Implications for a Bundled Payment Model

2019 ◽  
Vol 15 (6) ◽  
pp. e560-e567
Author(s):  
Martin C. Tom ◽  
Richard B. Ross ◽  
Shlomo A. Koyfman ◽  
David J. Adelstein ◽  
Robert R. Lorenz ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tertiary Care ◽  
Multivariable Analysis ◽  
Treatment Modalities ◽  
Trimodality Therapy ◽  
Payment Model ◽  
Bundled Payment ◽  
Number Of Treatment

PURPOSE: To determine which factors influence cost in head and neck cancer (HNC) to inform the development of a bundled payment model (BPM). METHODS: Patients with stages 0 to IVB (by American Joint Commission on Cancer, 7th edition) HNC of various sites and histology treated definitively at a single tertiary care center during 2013 were included. Clinical variables and direct cost data were obtained, and their associations were investigated using χ2, t, Wilcoxon rank sum, and analysis of variance testing. Results were used to develop a BPM. RESULTS: One hundred fifty patients were included; 87% were white, 74% were men, 48% had oropharyngeal cancer, and 58% had stage IVA disease. Treatment consisted of surgery alone (17%), radiation alone (11%), surgery plus radiation (14%), chemoradiation (45%), and surgery plus chemoradiation (13%). On multivariable analysis, both increasing group stage and number of treatment modalities used were significantly associated with higher cost. Given that stage often dictates treatment, we developed three cost tiers that were based on overall treatment modality. Tier A, the least costly, consisted of single-modality therapy with either surgery alone or radiation alone (median cost divided by the median overall cost of treatment, 0.54; 25th to 75th percentile range, 0.29 to 1.02), followed by tier B, which consisted of bimodality therapy with either chemoradiation or surgery plus radiation (1.03; range, 0.81 to 1.35), followed by tier C, which consisted of trimodality therapy with surgery plus chemoradiation (1.43; range, 1.10 to 1.96). CONCLUSION: The number of treatment modalities required is the primary driver of cost in HNC. These data can simplify development of a comprehensive HNC BPM.

Critical review of the follow-up protocol for head and neck cancer patients

2019 ◽  
Vol 133 (05) ◽  
pp. 424-429 ◽  
Author(s):  
E Kytö ◽  
E Haapio ◽  
H Minn ◽  
H Irjala
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Recurrent Disease ◽  
Tertiary Care ◽  
Easy Access ◽  
Care Centre ◽  
Tertiary Care Centre

AbstractObjectiveHead and neck cancer follow-up length, interval and content are controversial. Therefore, this study aimed to evaluate the efficacy of the follow-up protocol after curative treatment in head and neck cancer patients.MethodClinical data of 456 patients with new malignancy of the head and neck from a tertiary care centre district from 1999 to 2008 were analysed. Time from treatment, symptoms and second-line treatment outcomes of patients with recurrent disease were evaluated.ResultsA total of 94 (22 per cent) patients relapsed during the 5-year follow-up period; 90 per cent of recurrences were found within 3 years. Fifty-six per cent of the patients had subjective symptoms indicating a recurrence of the tumour. All recurrent tumours found during routine follow-up visits without symptoms were found within 34 months after completion of treatment.ConclusionRoutine follow up after three years is questionable; recurrent disease beyond this point was detected in only 2 per cent of patients. In this study, all late tumour recurrences had symptoms of the disease. Easy access to extra follow-up visits when symptoms occur could cover the need for late follow up.

scholarly journals Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines

2016 ◽  
Vol 130 (S2) ◽  
pp. S66-S67 ◽  
Author(s):  
C Nutting
Keyword(s):  
Head And Neck Cancer ◽  
United Kingdom ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Treatment Modalities ◽  
Current Role ◽  
Cancer Management ◽  
Recent Advances ◽  
The Uk

AbstractThis is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Radiotherapy is one of the key treatment modalities used in head and neck cancer management. This paper summarises the current role and some of the recent advances in radiotherapy in head and neck cancer management.

Sign in / Sign up

Export Citation Format

Share Document